Astragalus and fatigue

What 2 graded rows on astragalus agree on for fatigue, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Astragalus page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Astragalus page, with its PubMed record.

Supplement

Astragalus Choose another

2 rows · 125 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is a randomized trial of 64 people (2025) and found an improvement.

The rows run from 61 to 64 people, published from 2016 to 2025: 2 single studies.

2 improved

Grade DChronic fatigue after COVID-19 · Improved
RCT · n 64 · 2025 · Nurses in Iran with chronic fatigue syndrome after COVID-19
500 mg twice daily · Not stated in the abstract; follow-up 1 month after treatment
Chronic fatigue prevalence in the astragalus group fell to 13.8% at the end of treatment and 17.2% one month later; being in the placebo group was linked to higher odds of chronic fatigue (OR 12.36).
Row on the Astragalus page · PubMed 38834234 (opens PubMed)
Grade DPost-stroke fatigue · Improved
RCT · n 61 · 2016 · Adults with fatigue after stroke (Taiwan; 64 randomised)
2.8 g three times daily · 28 days
Brief Fatigue Inventory scores fell 17.8 points vs 8.0 with placebo; cognitive, social functioning and global quality-of-life scores also improved.
Row on the Astragalus page · PubMed 27773802 (opens PubMed)